VCYT:NSD-Veracyte Inc. (USD)

EQUITY | Diagnostics & Research | NASDAQ Global Market

Last Closing

USD 30.12

Change

0.00 (0.00)%

Market Cap

USD 0.21B

Volume

0.71M

Analyst Target

USD 38.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Veracyte Inc is engaged in the discovery, development and commercialization of molecular cytology solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 33.82B
NTRA Natera Inc

N/A

USD 21.03B
ICLR ICON PLC

N/A

USD 14.94B
ILMN Illumina Inc

N/A

USD 14.06B
MEDP Medpace Holdings Inc

N/A

USD 9.97B
EXAS EXACT Sciences Corporation

N/A

USD 8.47B
GH Guardant Health Inc

N/A

USD 4.85B
RDNT RadNet Inc

N/A

USD 3.68B
SHC Sotera Health Co

N/A

USD 3.23B
WGS GeneDx Holdings Corp.

N/A

USD 2.75B

ETFs Containing VCYT

GN0M:XETRA Global X Genomics & Biote.. 5.93 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 5.00 % 0.00 %

N/A

USD 8.06M
GNOG:LSE Global X Genomics & Biote.. 4.84 % 0.00 %

N/A

USD 9.10M
ARKG:LSE ARK Genomic Revolution UC.. 4.42 % 0.00 %

N/A

USD 9.33M
DDOC:F Global X Telemedicine & D.. 4.08 % 0.00 %

N/A

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.76 % 0.00 %

N/A

USD 2.77M
WBIO:LSE WisdomTree BioRevolution .. 2.30 % 0.00 %

N/A

USD 4.04M
WDNA WisdomTree BioRevolution .. 2.09 % 0.00 %

N/A

USD 1.96M
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

N/A

USD 0.06B
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

N/A
EDOC:LSE Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 4.95M
EDOG:LSE Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.33M

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.94% 47% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.94% 47% F 27% F
Trailing 12 Months  
Capital Gain 35.92% 81% B- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.92% 81% B- 87% B+
Trailing 5 Years  
Capital Gain 23.90% 66% D+ 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.90% 66% D+ 44% F
Average Annual (5 Year Horizon)  
Capital Gain 3.86% 56% F 52% F
Dividend Return 3.86% 54% F 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.92% 67% D+ 43% F
Risk Adjusted Return 9.00% 58% F 42% F
Market Capitalization 0.21B 76% C+ 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 102.65 13% 11%
Price/Book Ratio 2.11 46% 45%
Price / Cash Flow Ratio 33.03 14% 9%
Price/Free Cash Flow Ratio 45.62 10% 8%
Management Effectiveness  
Return on Equity 2.18% 84% 61%
Return on Invested Capital 1.31% 83% 60%
Return on Assets 1.39% 85% 69%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.